Research Progress of Treatment of Atherosclerosis by Targeting Interleukin-1β
Author:
  • Article
  • | |
  • Metrics
  • |
  • Reference
  • |
  • Related
  • |
  • Cited by
  • | |
  • Comments
    Abstract:

    Recent studies have shown that atherosclerosis is essentially a chronic vascular inflammatory disease, in which interleukin-1β plays a key regulatory role. Vascular endothelial cell damage caused by a variety of factors can lead to overexpression of interleukin-1β. By combination with interleukin-1 I receptor and activating NF-κB signaling pathway,interleukin-1β induces the synthesis of a large number of secondary inflammatory mediators, such as IL-6, TNFα. The results of animal experiment and clinical trials showed that antagonizing interleukin-1β signaling pathway was conducive to improving cardiac remodeling and reducing the risk of atherosclerotic cardiovascular events. The treatment of atherosclerosis targeting interleukin-1β has promising prospects for clinical application.

    Reference
    Related
    Cited by
Get Citation

LU Hao, LI Meng-Hao, XI Dan, LUO Tian-Tian,,GUO Zhi-Gang. Research Progress of Treatment of Atherosclerosis by Targeting Interleukin-1β[J]. Editorial Office of Chinese Journal of Arteriosclerosis,2015,23(04):411-416.

Copy
Share
Article Metrics
  • Abstract:
  • PDF:
  • HTML:
  • Cited by:
History
  • Received:June 16,2014
Article QR Code